Current concepts in antifungal pharmacology

Mayo Clinic Proceedings

Volumn 86, Issue 8, 2011, Pages 805-817

  Lewis, Russell E ^a  

^a UNIVERSITY OF HOUSTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CALCINEURIN INHIBITOR; CASPOFUNGIN; CONTRAST MEDIUM; ECHINOCANDIN; FLUCONAZOLE; FLUCYTOSINE; FOSCARNET; GRISEOFULVIN; ITRACONAZOLE; MICAFUNGIN; POSACONAZOLE; RIFAMPICIN; TERBINAFINE; TRIAZOLE DERIVATIVE; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; AREA UNDER THE CURVE; ASPERGILLUS; BINDING AFFINITY; BONE MARROW SUPPRESSION; CANDIDA; CELL MEMBRANE FLUIDITY; CONFERENCE PAPER; DIARRHEA; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG FORMULATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG MONITORING; DRUG POTENTIATION; DRUG SAFETY; EDEMA; GASTROINTESTINAL SYMPTOM; GRAFT VERSUS HOST REACTION; HUMAN; HYPERTENSION; HYPOKALEMIA; LIVER TOXICITY; LOADING DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MYCOSIS; NAUSEA; NEPHROTOXICITY; NONHUMAN; ONYCHOMYCOSIS; PHARMACODYNAMICS; PHOTOSENSITIVITY; RECEIVER OPERATING CHARACTERISTIC; SKIN INFECTION; VOMITING;

EID: 79960963679     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/mcp.2011.0247     Document Type: Conference Paper

References (109)

1. Dutcher JD. The discovery and development of amphotericin B. Dis Chest. 1968;54(suppl 1):296-298.
2. Rex JH, Bennett JE, Sugar AM, et al Candidemia Study Group; National Institute of Allergy and Infectious Diseases Mycoses Study Group. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N Engl J Med. 1994;331(20):1325-1330. (Pubitemid 24347001)
3. Kontoyiannis DP, Lewis RE. Antifungal drug resistance of pathogenic fungi. Lancet. 2002;359(9312):1135-1144. (Pubitemid 34270742)
4. Smith D, van de Velde V, Woestenborghs R, et al. The pharmacokinetics of oral itraconazole in AIDS patients. J Pharm Pharmacol. 1992;44(7):618-619.
5. Marr KA, Crippa F, Leisenring W, et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood. 2004;103(4):1527-1533. (Pubitemid 38168674)
6. Prentice AG, Glasmacher A. Making sense of itraconazole pharmacokinetics. J Antimicrob Chemother 2005;56(suppl 1);i17-i22. (Pubitemid 41236086)
7. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002;347(6):408-415. (Pubitemid 34851833)
8. Perfect JR, Marr KA, Walsh TJ, et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis. 2003;36(9):1122-1131. (Pubitemid 36549632)
9. Kauffman CA, Malani AN, Easley C, et al. Posaconazole. Nat Rev Drug Discov. 2007;6(3):183-184. (Pubitemid 46344622)
10. Rachwalski EJ, Wieczorkiewicz JT, Scheetz MH. Posaconazole: an oral triazole with an extended spectrum of activity. Ann Pharmacother. 2008;42(10):1429-1438.
11. Wingard JR, Carter SL, Walsh TJ, et al. Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood. 2010;116(24):5111- 5118.
12. Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 2007;356(4):348-359. (Pubitemid 46148777)
13. Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med. 2007;356(4):335-347. (Pubitemid 46148776)
14. Girmenia C. New generation azole antifungals in clinical investigation. Expert Opin Investig Drugs. 2009;18(9):1279-1295.
15. Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med. 2002;347(25):2020-2029. (Pubitemid 35461658)
16. Reboli AC, Rotstein C, Pappas PG, et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med. 2007;356(24):2472-2482. (Pubitemid 46919773)
17. Pappas PG, Rotstein CM, Betts RF, et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis. 2007;45(7):883-893. (Pubitemid 47580382)
18. Maertens J, Raad I, Petrikkos G, et al. Efficacy and safety of caspo-fungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis. 2004;39(11):1563-1571. (Pubitemid 39578526)
19. Sheehan DJ, Hitchcock CA, Sibley CM. Current and emerging azole antifungal agents. Clin Microbiol Rev. 1999;12(1):40-79. (Pubitemid 29055953)
20. Odds FC, Brown AJP, Gow NAR. Antifungal agents: mechanisms of action. Trends Microbiol. 2003;11(6):272-279. (Pubitemid 36725017)
21. Mann PA, Parmegiani RM, Wei SQ, et al. Mutations in Aspergillus fumigatus resulting in reduced susceptibility to posaconazole appear to be restricted to a single amino acid in the cytochrome p450 14 alpha-demethylase. Antimicrob Agents Chemother. 2003;47(2):577-581. (Pubitemid 36158085)
22. Mellado E, Garcia-Effron G, Alcazar-Fuoli L, et al. Substitutions at methionine 220 in the 14alpha-sterol demethylase (Cyp51A) of Aspergillus fumigatus are responsible for resistance in vitro to azole antifungal drugs. Antimicrob Agents Chemother. 2004;48(7):2747-2750. (Pubitemid 38823458)
23. Pfaller MA, Diekema DJ, Gibbs DL, et al. Candida krusei, a multidrug-resistant opportunistic fungal pathogen: geographic and temporal trends from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005. J Clin Microbiol. 2008;46(2):515-521. (Pubitemid 351231295)
24. Pfaller MA, Messer SA, Hollis RJ, et al. Variation in susceptibility of bloodstream isolates of Candida glabrata to fluconazole according to patient age and geographic location in the United States in 2001 to 2007. J Clin Microbiol. 2009;47(10):3185-3190.
25. Albengres E, Le Louet H, Tillement JP. Systemic antifungal agents: drug interactions of clinical significance. Drug Saf. 1998;18(2):83-97. (Pubitemid 28080742)
26. Ryder NS. Activity of terbinafine against serious fungal pathogens. Mycoses 1999;42(suppl 2):115-119. (Pubitemid 30253123)
27. Brajtburg J, Powderly WG, Kobayashi GS, et al. Amphotericin B: current understanding of mechanisms of action. Antimicrob Agents Chemother. 1990;34(2):183-188. (Pubitemid 20046861)
28. Groll AH, Piscitelli SC, Walsh TJ. Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development. Adv Pharmacol. 1998;44:343-500.
29. Cleary JD, Rogers PD, Chapman SW. Variability in polyene content and cellular toxicity among deoxycholate amphotericin B formulations. Pharmacotherapy. 2003;23(5):572-578. (Pubitemid 36539037)
30. Rogers PD, Jenkins JK, Chapman SW, et al. Amphotericin B activation of human genes encoding for cytokines. J Infect Dis. 1998;178(6):1726-1733. (Pubitemid 28558146)
31. Saliba F, Dupont B. Renal impairment and amphotericin B formulations in patients with invasive fungal infections. Med Mycol. 2008;46(2):97-112. (Pubitemid 351372328)
32. Chamilos G, Kontoyiannis DP. Update on antifungal drug resistance mechanisms of Aspergillus fumigatus. Drug Resist Updat. 2005;8(6):344-358. (Pubitemid 43358058)
33. Blum G, Perkhofer S, Haas H, et al. Potential basis for amphotericin B resistance in Aspergillus terreus. Antimicrob Agents Chemother. 2008;52(4):1553-1555. (Pubitemid 351522034)
34. Bennett JE. Echinocandins for candidemia in adults without neutropenia. N Engl J Med. 2006;355(11):1154-1159. (Pubitemid 44394921)
35. Douglas CM, D'Ippolito JA, Shei GJ, et al. Identification of the FKS1 gene of Candida albicans as the essential target of 1,3-beta-D-glucan synthase inhibitors. Antimicrob Agents Chemother. 1997;41(11):2471-2479. (Pubitemid 27467559)
36. Denning DW. Echinocandin antifungal drugs. Lancet. 2003;362(9390):1142- 1151. (Pubitemid 37222342)
37. Perlin DS. Resistance to echinocandin-class antifungal drugs. Drug Resist Updat. 2007;10(3):121-130. (Pubitemid 47031054)
38. Diasio RB, Bennett JE, Myers CE. Mode of action of 5-fluorocytosine. Biochem Pharmacol. 1978;27(5):703-707. (Pubitemid 8313181)
39. Francis P, Walsh TJ. Evolving role of flucytosine in immunocompromised patients - new insights into safety, pharmacokinetics, and antifungal therapy. Clin Infect Dis 1992;15(6):1003-1018.
40. Johnston A. The pharmacokinetics of voriconazole. Br J Clin Pharmacol. 2003;56(suppl 1):1. (Pubitemid 37491726)
41. Stevens DA. Itraconazole in cyclodextrin solution. Pharmacotherapy. 1999;19(5):603-611. (Pubitemid 29211805)
42. Krishna G, Moton A, Ma L, et al. Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. Antimicrob Agents Chemother. 2009;53(3):958-966.
43. Alffenaar JW, van Assen S, van der Werf TS, et al. Omeprazole significantly reduces posaconazole serum trough level [letter]. Clin Infect Dis. 2009;48(6):839.
44. Courtney R, Wexler D, Radwanski E, et al. Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults. Br J Clin Pharmacol. 2004;57(2):218-222. (Pubitemid 38223535)
45. Ezzet F, Wexler D, Courtney R, et al. Oral bioavailability of posacon-azole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage recommendations. Clin Pharmacokinet. 2005;44(2):211-220. (Pubitemid 40188942)
46. Theuretzbacher U, Ihle F, Derendorf H. Pharmacokinetic/pharmacodynamic profile of voriconazole. Clin Pharmacokinet. 2006;45(7):649-663. (Pubitemid 43990568)
47. Desta Z, Zhao X, Shin JG, et al. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet. 2002;41(12):913-958. (Pubitemid 35168437)
48. Neely M, Rushing T, Kovacs A, et al. Voriconazole pharmacokinetics and pharmacodynamics in children. Clin Infect Dis. 2010;50(1):27-36.
49. Walsh TJ, Driscoll T, Milligan PA, et al. Pharmacokinetics, safety, and tolerability of voriconazole in immunocompromised children. Antimicrob Agents Chemother. 2010;54(10):4116-4123.
50. Bruggemann RJ, Alffenaar JW, Blijlevens NM, et al. Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clin Infect Dis. 2009;48(10):1441-1458.
51. Tucker RM, Denning DW, Hanson LH, et al. Interaction of azoles with rifampin, phenytoin, and carbamazepine: in vitro and clinical observations. Clin Infect Dis. 1992;14(1):165-174.
52. Purkins L, Wood N, Ghahramani P, et al. Coadministration of voriconazole and phenytoin: pharmacokinetic interaction, safety, and toleration. Brit J Clin Pharmacol. 2003;56(suppl 1):37-44. (Pubitemid 37491732)
53. Geist MJ, Egerer G, Burhenne J, et al. Induction of voriconazole metabolism by rifampin in a patient with acute myeloid leukemia: importance of interdisciplinary communication to prevent treatment errors with complex medications. Antimicrob Agents Chemother. 2007;51(9):3455-3456. (Pubitemid 350067579)
54. Hohmann C, Kang EM, Jancel T. Rifampin and posaconazole coadministration leads to decreased serum posaconazole concentrations. Clin Infect Dis. 2010;50(6):939-940.
55. Lewis RE. Managing drug interactions in the patient with aspergillosis. Med Mycol. 2006;44(suppl):S349-S356.
56. Gubbins PO, McConnell SA, Amsden JR. Antifungal agents. In: Piscitelli SC, Rodvold KA, eds. Drug Interactions in Infectious Diseases. 2nd ed. Totowa, NJ: Humana Press; 2005:289-338.
57. Dodds-Ashley ES, Lewis RE, Lewis JS II, et al. Pharmacology of systemic antifungal agents. Clin Infect Dis. 2006;43(suppl 1):S28-S39.
58. Dodds-Ashley E. Management of drug and food interactions with azole antifungal agents in transplant recipients. Pharmacotherapy. 2010;30(8):842-854.
59. Saad AH, DePestel DD, Carver PL. Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants. Pharmacotherapy. 2006;26(12):1730-1744. (Pubitemid 44885328)
60. Black KE, Baden LR. Fungal infections of the CNS: treatment strategies for the immunocompromised patient. CNS Drugs. 2007;21(4):293-318. (Pubitemid 46598450)
61. Pagano L, Caira M, Falcucci P, et al. Fungal CNS infections in patients with hematologic malignancy. Expert Rev Anti Infect Ther. 2005;3(5):775-785. (Pubitemid 41535399)
62. Schwartz S, Ruhnke M, Ribaud P, et al. Improved outcome in central nervous system aspergillosis, using voriconazole treatment. Blood. 2005;106(8):2641-2645. (Pubitemid 41510735)
63. Imai JK, Singh G, Clemons KV, et al. Efficacy of posaconazole in a murine model of central nervous system aspergillosis. Antimicrob Agents Chemother. 2004;48(10):4063-4066. (Pubitemid 39304651)
64. Drusano GL. Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'. Nat Rev Microbiol. 2004;2(4):289-300. (Pubitemid 39490099)
65. Andes D, van Ogtrop M. In vivo characterization of the pharmacodynamics of flucytosine in a neutropenic murine disseminated candidiasis model. Antimicrob Agents Chemother. 2000;44(4):938-942. (Pubitemid 30165273)
66. Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of America. Clin Infect Dis. 2010;50(3):291-322.
67. Andes D, Stamsted T, Conklin R. Pharmacodynamics of amphotericin B in a neutropenic-mouse disseminated-candidiasis model. Antimicrob Agents Chemother. 2001;45(3):922-926. (Pubitemid 32182046)
68. Wiederhold NP, Tam VH, Chi J, et al. Pharmacodynamic activity of amphotericin B deoxycholate is associated with peak plasma concentrations in a neutropenic murine model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother. 2006;50(2):469-473. (Pubitemid 43190954)
69. Andes D, Safdar N, Marchillo K, et al. Pharmacokinetic-pharmacodynamic comparison of amphotericin B (AMB) and two lipid-associated AMB preparations, liposomal AMB and AMB lipid complex, in murine candidiasis models. Antimicrob Agents Chemother. 2006;50(2):674-684. (Pubitemid 43190982)
70. Hong Y, Shaw PJ, Nath CE, et al. Population pharmacokinetics of liposomal amphotericin B in pediatric patients with malignant diseases. Antimicrob Agents Chemother. 2006;50(3):935-942. (Pubitemid 43327797)
71. Cornely OA, Maertens J, Bresnik M, et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis. 2007;44(10):1289-1297. (Pubitemid 46717290)
72. Andes D, Diekema DJ, Pfaller MA, et al. In Vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species. Antimicrob Agents Chemother. 2010;54(6):2497-2506.
73. Louie A, Deziel M, Liu W, et al. Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity. Antimicrob Agents Chemother. 2005;49(12):5058-5068. (Pubitemid 41778921)
74. Wiederhold NP, Kontoyiannis DP, Chi J, et al. Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity. J Infect Dis. 2004;190(8):1464-1471. (Pubitemid 39332186)
75. Pfaller MA, Diekema DJ, Andes D, et al. Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria. Drug resist updat. 2011;14(3):164-176.
76. Andes D. Pharmacokinetics and pharmacodynamics of antifungals. Infect Dis Clin North Am. 2006;20(3):679-697. (Pubitemid 44375115)
77. Baddley JW, Patel M, Bhavnani SM, et al. Association of fluconazole pharmacodynamics with mortality in patients with candidemia. Antimicrob Agents Chemother. 2008;52(9):3022-3028.
78. Andes D, van Ogtrop H. Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis infection model. Antimicrob Agents Chemother. 1999;43(9):2116-2120. (Pubitemid 29421186)
79. Andes D, Marchillo K, Conklin R, et al. Pharmacodynamics of a new triazole, posaconazole, in a murine model of disseminated candidiasis. Antimicrob Agents Chemother. 2004;48(1):137-142. (Pubitemid 38040189)
80. Howard SJ, Lestner JM, Sharp A, et al. Pharmacokinetics and pharmacodynamics of posaconazole for invasive pulmonary aspergillosis: clinical implications for antifungal therapy. J Infect Dis. 2011;203(9):1324-1332.
81. Pai MP, Turpin RS, Garey KW. Association of fluconazole area under the concentration-time curve/MIC and dose/MIC ratios with mortality in nonneutropenic patients with candidemia. Antimicrob Agents Chemother. 2007;51(1):35-39. (Pubitemid 46047684)
82. Clancy CJ, Kauffman CA, Morris A, et al. Correlation of fluconazole MIC and response to therapy for patients with candidemia due to C. albicans and non-C. albicans spp: results of a multicenter prospective study of candidemia. In: Proceedings of the 36th Annual Meeting of the Infectious Diseases Society of America. Denver, CO: 1998.
83. Andes D. Clinical pharmacodynamics of antifungals. Infect Dis Clin North Am. 2003;17(3):635-649. (Pubitemid 38029157)
84. Pfaller MA, Andes D, Diekema DJ, et al. Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: time for harmonization of CLSI and EUCAST broth microdilution methods. Drug resist updat. 2010;13(6):180-195.
85. Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2008;46(3):327-360. (Pubitemid 351265310)
86. Andes D, Pascual A, Marchetti O. Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrob Agents Chemother. 2009;53(1):24-34.
87. Hope WW, Billaud EM, Lestner J, et al. Therapeutic drug monitoring for triazoles. Curr Opin Infect Dis. 2008;21(6):580-586.
88. Kauffman CA. Histoplasmosis. Clin Chest Med. 2009;30(2):217-225, v.
89. Pasqualotto AC, Howard SJ, Moore CB, et al. Flucytosine therapeutic monitoring: 15 years experience from the UK. J Antimicrob Chemother. 2007;59(4):791-793. (Pubitemid 47073421)
90. Glasmacher A, Hahn C, Molitor E, et al. Itraconazole for antifungal prophylaxis in neutropenic patients: a meat-analysis of 2181 patients. In: Proceedings of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago IL: 2001.
91. Glasmacher A, Hahn C, Molitor E, et al. Itraconazole trough concentrations in antifungal prophylaxis with six different dosing regimens using hydroxypropyl-beta- cyclodextrin oral solution or coated-pellet capsules. Mycoses. 1999;42(11-12):591-600. (Pubitemid 30053362)
92. Denning DW, Tucker RM, Hanson LH, Hamilton JR, Stevens DA. Itraconazole therapy for cryptococcal meningitis and cryptococcosis. Arch Intern Med. 1989;149(10):2301-2308. (Pubitemid 19258176)
93. Denning DW, Tucker RM, Hanson LH, et al. Treatment of invasive aspergillosis with itraconazole. Am J Med. 1989;86(6):791-800. (Pubitemid 19148096)
94. Cartledge JD, Midgely J, Gazzard BG. Itraconazole solution: higher serum drug concentrations and better clinical response rates than the capsule formulation in acquired immunodeficiency syndrome patients with candidosis. J Clin Pathol. 1997;50(6):477-480. (Pubitemid 27315993)
95. Lestner JM, Roberts SA, Moore CB, et al. Toxicodynamics of itraconazole: implications for therapeutic drug monitoring. Clin Infect Dis. 2009;49(6):928-930.
96. Trifilio S, Pennick G, Pi J, et al. Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients. Cancer. 2007;109(8):1532-1535. (Pubitemid 46595688)
97. Trifilio S, Ortiz R, Pennick G, et al. Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 2005;35(5):509-513. (Pubitemid 40403355)
98. Tan K, Brayshaw N, Tomaszewski K, et al. Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities. J Clin Pharmacol. 2006;46(2):235-243. (Pubitemid 43146453)
99. VFEND (voriconazole) Tablets, VFEND I.V., (voriconazole) VFEND (voriconazole) Oral Suspension [package insert]. New York, NY: Pfizer; 2004. http://www.accessdata.fda.gov/drugsatfda-docs/label/2006/021266s18,021267s19, 021630s10lbl.pdf. Accessed June 28, 2011.
100. Smith J, Safdar N, Knasinski V, et al. Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother. 2006;50(4):1570-1572.
101. Pascual A, Calandra T, Bolay S, et al. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves safety and efficacy outcomes. Clin Infect Dis. 2007;46(2):201-211. (Pubitemid 351269158)
102. Kohl V, Muller C, Cornely OA, et al. Factors influencing pharmacokinetics of prophylactic posaconazole in patients undergoing allogeneic stem cell transplantation. Antimicrob Agents Chemother. 2010;54(1):207-212.
103. Krishna G, Parsons A, Kantesaria B, et al. Evaluation of the pharmacokinetics of posaconazole and rifabutin following co-administration to healthy men. Curr Med Res Opin. 2007;23(3):545-552. (Pubitemid 46456902)
104. AbuTarif MA, Krishna G, Statkevich P. Population pharmacokinetics of posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome. Curr Med Res Opin. 2010;26(2):397-405.
105. Walsh TJ, Raad I, Patterson TF, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis. 2007;44(1):2-12. (Pubitemid 44968977)
106. Jang SH, Colangelo PM, Gobburu JV. Exposure-response of posaconazole used for prophylaxis against invasive fungal infections: evaluating the need to adjust doses based on drug concentrations in plasma. Clin Pharmacol Ther. 2010;88(1):115-119.
107. Ahmad SR, Singer SJ, Leissa BG. Congestive heart failure associated with itraconazole. Lancet. 2001;357(9270):1766-1767. (Pubitemid 32524211)
108. Riahi RR, Cohen PR. Voriconazole-associated phototoxicity [letter]. Dermatol Online J. 2011;17(2):15.
109. Morice C, Acher A, Soufir N, et al. Multifocal aggressive squamous cell carcinomas induced by prolonged voriconazole therapy: a case report. Case Report Med. 2010;2010:351084.